Interestingly, blockers of ADAM17 have been considered for clinical trials in several diseases including cancer and type 1 and type 2 diabetes (NCT04630769, NCT02141451, NCT00312780, NCT04557228, NCT01223196). Here, ADAM17 is linked to cancer.